Premium
Free interferon‐α/β receptors in the circulation of patients with adenocarcinoma
Author(s) -
Ambrus Julian L.,
Dembinski Wlodzimierz,
Ambrus Julian L.,
Sykes Donald E.,
Akhter Selina,
Kulaylat Mahmoud N.,
Islam Abul,
Chadha Kailash C.
Publication year - 2003
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.11843
Subject(s) - medicine , adenocarcinoma , carcinoma , lymphoma , renal cell carcinoma , alpha interferon , oncology , cancer , gastroenterology , immunology , interferon
BACKGROUND Many viral and neoplastic diseases are resistant to interferon‐α/β (IFN‐α/β) therapy or develop resistance during the course of IFN treatment. In patients with viral diseases, the authors identified four IFN inhibitors, of which the most important, most likely is a free IFN receptor of type 1 appearing in the circulation that captures and neutralizes IFN‐α/β. METHODS Ninety‐one cancer patients and 25 healthy individuals were studied. Free circulating IFN receptor‐α/β type 1 was studied. The patients were ages 35–75 years. The diagnoses were 24 cases of colon carcinoma, 7 cases of prostate carcinoma, 16 cases of breast carcinoma, 8 cases of ovarian carcinoma, 9 cases of uterine carcinoma, 5 cases of lung carcinoma, 3 cases of astrocytoma, 4 cases of transitional cell carcinoma of the bladder, 1 case of osteosarcoma, 3 cases of multiple myeloma, 4 cases of Hodgkin disease, 2 cases of non‐Hodgkin lymphoma, 3 cases of myelodysplastic syndrome, and 2 disseminated tumors of unknown origin. RESULTS All patients were found to have increased free IFN receptor‐α/β type 1 in the circulation, with the highest levels reported in patients with adenocarcinoma. CONCLUSIONS High IFN inhibitory activity in patients with cancer may be a significant factor in their increased susceptibility to progressive disease, infectious complications, and resistance to IFN therapy. Ongoing studies are being performed with the objective of overcoming this inhibitory activity. Cancer 2003;98:2730–3. © 2003 American Cancer Society.